AR076555A1 - GLICAN ANTIGEN. USE. ANTIBODY. VACCINE. METHOD FOR MANUFACTURING VACCINE - Google Patents

GLICAN ANTIGEN. USE. ANTIBODY. VACCINE. METHOD FOR MANUFACTURING VACCINE

Info

Publication number
AR076555A1
AR076555A1 ARP100101582A ARP100101582A AR076555A1 AR 076555 A1 AR076555 A1 AR 076555A1 AR P100101582 A ARP100101582 A AR P100101582A AR P100101582 A ARP100101582 A AR P100101582A AR 076555 A1 AR076555 A1 AR 076555A1
Authority
AR
Argentina
Prior art keywords
antigen
vaccine
antibody
ldnf
gal
Prior art date
Application number
ARP100101582A
Other languages
Spanish (es)
Inventor
Irma Marianne Die
Boris Tefsen
Die Irma Marianne Van
Original Assignee
Stichting Tech Wetenschapp
Vereniging Voor Christelijk Hoger Onderwijs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Tech Wetenschapp, Vereniging Voor Christelijk Hoger Onderwijs filed Critical Stichting Tech Wetenschapp
Publication of AR076555A1 publication Critical patent/AR076555A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Abstract

La presente solicitud se refiere al campo de la inmunología parasitaria veterinaria. En forma más específica, la solicitud se refiere a una estructura de carbohidratos util para el tratamiento inmunoprotector y para la prevencion o reduccion de las infecciones causadas por los nematodos parasíticos en los rumiantes. Particularmente, la solicitud se refiere a un antígeno que comprende la estructura de carbohidratos, a un anticuerpo específico para la estructura de carbohidratos, a una vacuna que comprende el antígeno o el anticuerpo, al uso del antígeno, el anticuerpo o la vacuna, y a los métodos de tratamiento y métodos de fabricacion. Reivindicacion 1: Un antígeno que comprende un carbohidrato correspondiente a la formula estructural Gala1-3GalNAcb1-4(Fuca1-3)GlcNAc (en lo sucesivo: Gal-LDNF). Reivindicacion 2: El antígeno de acuerdo con la reivindicacion 1, que comprende la Gal-LDNF en una estructura química de la formula: Gal-LDNF-R, caracterizado porque R denota una estructura inmunogénica, a la cual se adjunta la unidad de GlcNAc de la Gal-LDNF. Reivindicacion 3: El antígeno de acuerdo con la reivindicacion 2, caracterizado porque la estructura inmunogénica R se selecciona entre el grupo que consiste en carbohidratos, proteínas y lípidos. Reivindicacion 5: El antígeno de acuerdo con la reivindicacion 4, caracterizado porque R2 comprende, adicionalmente, una porcion de diaminopiridina que adjunta R2 a R1.The present application refers to the field of veterinary parasitic immunology. More specifically, the application refers to a carbohydrate structure useful for immunoprotective treatment and for the prevention or reduction of infections caused by parasitic nematodes in ruminants. Particularly, the application refers to an antigen comprising the carbohydrate structure, a specific antibody for the carbohydrate structure, a vaccine comprising the antigen or the antibody, the use of the antigen, the antibody or the vaccine, and treatment methods and manufacturing methods. Claim 1: An antigen comprising a carbohydrate corresponding to the structural formula Gala1-3GalNAcb1-4 (Fuca1-3) GlcNAc (hereinafter: Gal-LDNF). Claim 2: The antigen according to claim 1, comprising Gal-LDNF in a chemical structure of the formula: Gal-LDNF-R, characterized in that R denotes an immunogenic structure, to which the GlcNAc unit of the Gal-LDNF. Claim 3: The antigen according to claim 2, characterized in that the immunogenic structure R is selected from the group consisting of carbohydrates, proteins and lipids. Claim 5: The antigen according to claim 4, characterized in that R2 additionally comprises a portion of diaminopyridine that attaches R2 to R1.

ARP100101582A 2009-05-11 2010-05-10 GLICAN ANTIGEN. USE. ANTIBODY. VACCINE. METHOD FOR MANUFACTURING VACCINE AR076555A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09159945 2009-05-11
US17742209P 2009-05-12 2009-05-12

Publications (1)

Publication Number Publication Date
AR076555A1 true AR076555A1 (en) 2011-06-22

Family

ID=40941929

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101582A AR076555A1 (en) 2009-05-11 2010-05-10 GLICAN ANTIGEN. USE. ANTIBODY. VACCINE. METHOD FOR MANUFACTURING VACCINE

Country Status (3)

Country Link
AR (1) AR076555A1 (en)
UY (1) UY32621A (en)
WO (1) WO2010130683A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046988B2 (en) 2014-08-04 2021-06-29 Synaffix B.V. Process for the modification of a glycoprotein using a β-(1,4)-N-acetylgalactosaminyl transferase or a mutant thereof
NO3134520T3 (en) 2015-04-23 2018-05-19

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPS021402A0 (en) * 2002-01-30 2002-02-21 Agresearch Limited Novel monoclonal antibody and nematode larval antigens

Also Published As

Publication number Publication date
WO2010130683A1 (en) 2010-11-18
UY32621A (en) 2010-12-31

Similar Documents

Publication Publication Date Title
AR121611A2 (en) GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
MX2021015775A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof.
PE20150200A1 (en) FORMULATION OF ANTIBODIES
DOP2012000312A (en) SUBSTITUTED TRIAZOLOPIRIDINS
SV2011003888A (en) COMPOUNDS THAT EXPAND HEMATOPOIETIC MOTHER CELLS
EP3616716A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PA8840801A1 (en) DIOXA-BICYCLE DERIVAOS [3.2.1] OCTANO-2,3,4-TRIOL
BR112013023876A2 (en) pyrroltriazinone derivatives as pi3k inhibitors
PE20131055A1 (en) SYSTEM TO PRODUCE ENERGY THROUGH THE ACTION OF WAVES
AR082630A1 (en) ANTI-TENASCINE-C A2 ANTIBODIES AND METHODS OF USE
ECSP099465A (en) SUCCINATE SALT POLYMORPHES 2- [6- (3-AMINO-PIPERIDIN-1-ILO) -3-METIL-2,4-DIOXO-3,4-DIHIDRO-2H-PIRIMIDIN-1-ILMETIL] -4-FLUORO -BENZONITRILE AND METHODS
BR112013029013A2 (en) OCCLUSION DEVICE
AR060543A1 (en) COMPOSITION THAT INCLUDES AT LEAST A WATERPROOF PHASE AND AT LEAST A FAT PHASE THAT INCLUDES IVERMECTINE
BRPI0809275A2 (en) Process for preparing crystalline particles of an active principle in the presence of ultrasonic irradiation.
PE20190458A1 (en) NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS OF THE SAME
CL2015002724A1 (en) Methods to treat crohn's disease using an anti-il23 antibody
CL2015001111A1 (en) Adjuvant composition comprising a carbohydrate attached to the chitosan forming a schiff base; vaccine formulation that comprises it; elaboration method; and use of the vaccine.
CR10143A (en) ANTIGENS OF DES-N-ACETYL-SIALIC ACID, ANTIBODIES FOR THE SAME AND METHODS OF USE IN CANCER THERAPY
EA201500701A1 (en) METHOD OF CREATING A VACCINE AGAINST MYCOPLASM
CL2013001935A1 (en) Aqueous acid formulation comprising a first fluorocarbon linked peptide; method to obtain said formulation; use of said formulation to treat or prevent pathogenic infection, an autoimmune disease or cancer.
AR090481A1 (en) USE OF A SOFT ALKAL AGENT IN THE RECOVERY OF PETROLEUM
BRPI1010546B8 (en) process for producing compound, method for isolating and purifying solvate crystals of compound, and use of compound
ECSP12012203A (en) PROCEDURE TO PRODUCE DERIVATIVES OF PYRIPYROPEN
CO6592111A2 (en) Procedure of activation and conjugation of biomolecules
CL2007003859A1 (en) Method for removing arsenic comprising contacting the solution with a rare earth precipitating agent to precipitate arsenic and obtaining partially liberated solution of arsenic and arsenic loaded agent, contacting the separated solution with a second portion of precipitating agent; and apparatus for separating arsenic.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal